Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Gracell Biotechnologies Inc.

Gracell is developing cell therapy that delivers fast, deep and durable responses for cancer and autoimmune disease patients. The company is focused on discovering and developing innovative and highly efficacious cell therapies to address major industry challenges and fulfill unmet medical needs, self-described as aiming to disrupt conventional approaches to CAR-T cell therapies.

NASDAQ:GRCL

Gracell

Last Close

10.24

21/02 21:00

Market Cap

989.87M

Beta: −1.83

Volume Today

6.37M

Avg: 131.30K

PE Ratio

−12.25

PFCF: -

People Not Available